Manufacturing Patent Listings Could Be Part Of Follow-On Biologics Pathway
Legislative consideration of a potential approval pathway for follow-on biologics will likely include discussion about creating a system for listing and challenging biologic patents
You may also be interested in...
FDA is unlikely to proceed with developing a follow-on biologics pathway until a permanent commissioner is confirmed, a Senate Health Committee staffer said at a Food & Drug Law Institute conference in Washington, D.C., Nov. 16
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011